VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Menactra
Vaccine Information
  • Vaccine Name: Menactra
  • Target Pathogen: Neisseria meningitidis
  • Target Disease: Meningitis
  • Product Name: Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine
  • Tradename: Menactra
  • Manufacturer: Sanofi Pasteur Inc.
  • Vaccine Ontology ID: VO_0000071
  • CDC CVX code: 114
  • Type: Conjugate vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1725), Canada
  • Host Species for Licensed Use: Human
  • Allergen: Latex
  • Preparation: Cultured on Mueller Hinton agar and grown in Watson Scherp media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration (FDA: Menactra).
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: Store at 2° to 8°C (35° to 46°F). DO NOT FREEZE.
  • Approved Age for Licensed Use: 2-55 years of age.
  • Contraindication: This vaccine should not be administered to anyone with known hypersensitivity to any component of Menactra vaccine including diphtheria toxoid, or a life-threatening reaction after previous administration of a vaccine containing similar components (FDA: Menactra).
  • Description: Contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. Menactra vaccine is not indicated for immunization against diphtheria (FDA: Menactra).
Host Response

Human Response

  • Immune Response: Clinical studies reported antibodies were seen in 90-100% of those who were vaccinated with Menactra (FDA: Menactra).
  • Side Effects: Side effects of vaccination include: injection site reactions, headache, fatigue, irritability and fever.
References
FDA: Menactra: FDA: Menactra [https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf]